PA
TKNO icon

PharVision Advisers’s Alpha Teknova TKNO Stock Holding History

PharVision Advisers’s Portfolio TKNO Stock Details TKNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-37,645
Closed -$233K – 997
2025
Q3 		$233K Buy
37,645
+19,149
+104% +$90K 0.13% 384
2025
Q2 		$90.8K Buy
+18,496
New +$109K 0.13% 255

Other funds holding TKNO

RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return

PharVision Advisers's TKNO Position: Q4 2025 in Review

PharVision Advisers sold out of Alpha Teknova (TKNO) in Q4 2025, closing a stake of 37,645 shares — an estimated $233K sold.

PharVision Advisers first reported a position in TKNO in Q2 2025 and held it in 2 quarters. The position peaked at $233K in Q3 2025. 69 funds tracked by Wall St. Rank hold TKNO as of Q4 2025.

  • PharVision Advisers reported no remaining Alpha Teknova position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 37,645 Alpha Teknova shares in Q4 2025, an estimated $233K.
  • PharVision Advisers first reported a position in Alpha Teknova in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Alpha Teknova position peaked at $233K in Q3 2025.
  • 69 funds tracked by Wall St. Rank held Alpha Teknova as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.